Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06545942 · ClinicalTrials.gov registry record · Phase 1

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by MOMA Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
220
Enrollment target
18
Study locations

NCT06545942 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by MOMA Therapeutics. The registered enrollment target is 220 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06545942, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by MOMA Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
220 participants
Enrollment target
18
Study locations

Study Summary

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.

Conditions Studied

Breast Cancer Prostate Cancer Ovarian Cancer Advanced Solid Tumor Pancreas Cancer Metastatic Solid Tumor Homologous Recombination Deficiency

Interventions

  • DRUG Olaparib
  • DRUG MOMA-313

Study Locations (18)

Other

  • Investigative Site #114 - Barcelona
  • Investigative Site #116 - Barcelona
  • Investigative Site #115 - Madrid
  • Investigative Site #113 - London
  • Investigative Site #117 - Manchester
  • Investigative Site #118 - Newcastle upon Tyne

California

  • Investigative Site #101 - La Jolla
  • Investigative Site #111 - San Francisco

New York

  • Investigative Site #103 - New York
  • Investigative Site #106 - New York

Arizona

  • Investigative Site #108 - Goodyear

Florida

  • Investigative Site #104 - Lake Mary

Missouri

  • Investigative Site #110 - St Louis

Pennsylvania

  • Investigative Site #109 - Philadelphia

South Carolina

  • Investigative Site #107 - Myrtle Beach

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2024-08-13
Est. Completion 2027-11-30
Phase Phase 1

Sponsor

MOMA Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06545942

The ClinicalTrials.gov registry entry for NCT06545942 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower). The listed sponsor is MOMA Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.

NCT06545942 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Other, California, New York.

Frequently Asked Questions

What is clinical trial NCT06545942 about?

NCT06545942 is a clinical study titled "Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors". This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients wi...

What is the current status of trial NCT06545942?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2024-08-13. Estimated completion is 2027-11-30.

What conditions does trial NCT06545942 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Ovarian Cancer, Advanced Solid Tumor, Pancreas Cancer.

What interventions are being tested in trial NCT06545942?

The interventions under investigation include: Olaparib (DRUG), MOMA-313 (DRUG).

Who is sponsoring clinical trial NCT06545942?

This trial is sponsored by MOMA Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06545942 being conducted?

This trial has 18 study locations across Arizona, California, Florida, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.